Background: Alkaline phosphatase (ALP) is a strong prognostic factor in patients with metastatic colorectal cancer (MCRC). Patients with ALP more than three times the upper limit of normal (ULN) were excluded from our previous studies evaluating chemotherapy. An exploratory cohort of patients with ALP >3 ULN was included in the OPTIMOX1 study.
introduction
Colorectal cancer (CRC) is one of the most common malignancies and the second most common cause of cancer death in the United States and most European countries. Approximately half of CRC patients develop metastatic disease [1] . The prognosis for these patients is poor, although palliative chemotherapy has been able to prolong survival and improve quality of life compared with best supportive care [2] . Clinical trials in metastatic colorectal cancer (MCRC) have revealed considerable heterogeneity in survival rates. This can be explained not only by the differing treatment schedules but also by differences in patient characteristics and prognostic factors.
The FOLFOX4 regimen became established as a standard first-line therapy for advanced CRC after the European C95 and the US N9741 studies which demonstrated superiority, respectively, over leucovorin (LV)/5-fluorouracil (5-FU) and LV/5-FU bolus and irinotecan [3, 4] .
More recently, the OPTIMOX1 study demonstrated that oxaliplatin can be safely stopped after six cycles of a FOLFOX regimen, with subsequent reintroduction continuing to prove clinically effective [5] .
There is currently growing interest in stratifying CRC patients according to prognosis, with a view to providing appropriate treatment. One key prognostic factor in patients with metastatic disease is alkaline phosphatase (ALP) number of metastatic sites [6] . In our previous experience, we found that ALP more than three times the upper limit of normal value (ULN) of the laboratory was also associated with early death, and patients with ALP >3 ULN were consequently excluded from our previous randomized studies [3, 7] . To investigate the treatment of poor prognosis patients treated with a FOLFOX regimen, an exploratory cohort of patients with ALP 3-5 ULN was therefore included in the OPTIMOX1 study which compared two different strategies and oxaliplatin dose intensity. The results of this cohort are reported in this paper.
patients and methods

patient selection
The patients in this study had to have ALP 3-5 ULN, as well as meeting the eligibility criteria for inclusion in the parent OPTIMOX1 study: adenocarcinoma of the colon or rectum, unresectable metastases, at least one bidimensionally measurable lesion of ‡1 cm or a nonmeasurable evaluable lesion, adequate bone marrow and renal function (creatinine level £3 ULN), World Health Organization (WHO) performance status of zero to two, age 18-80 years and no previous chemotherapy for metastatic disease. Previous adjuvant chemotherapy, if given, was to have been completed at least 6 months before inclusion. Patients with central nervous system metastases, second malignancies, bowel obstruction, peripheral neuropathy grade > 1, symptomatic angina pectoris or disease confined to previous radiation fields were excluded. Written informed consent was required and the ethical committee approved the study at all participating centers. No external review of computed tomography (CT) scan was performed in this study. In both arms, treatment was continued until progression on FOLFOX therapy, unacceptable toxicity or the patient's choice to discontinue. In case of progression during sLV5-FU2 alone and sensory neuropathy grade < 2, reintroduction of oxaliplatin was scheduled in arm B and allowed in arm A.
National Cancer Institute-Common Toxicity Criteria version 2.0 were used to assess toxicity [8] . Treatment course could be delayed up to 2 weeks until recovery from toxicity grade £2.
evaluation criteria
Physical examinations and blood counts were carried out every cycle. Hepatic, renal function tests and CT scans of measurable lesions were assessed at baseline and repeated after four cycles, six cycles and then every six cycles. Tumor response was evaluated according to WHO criteria. Complete response (CR) was defined as the complete disappearance of all known disease, partial response (PR) as a decrease of at least 50% of the sum of the products of the diameters of measurable lesions. Stable disease (SD) was defined as a decrease of less than 50% or an increase of less than 25% of measurable lesions, and progressive disease (PD) as an increase of at least 25% of measurable lesion or the appearance of new malignant lesion(s). External review of CT scans was not carried out.
The primary assessment criterion for the overall OPTIMOX1 study was duration of disease control (DDC) [5] . Secondary assessments were progression-free survival (PFS), overall survival (OS), response rates and tolerance.
statistical considerations
Randomization was carried out using a minimization technique [9] , stratifying patients by center, performance status (0-1 versus 2), number of metastatic sites involved (1 versus >1), age (18-50 years versus 51-75 versus 76-80 years) and baseline ALP (£3 ULN versus >3 and £5 ULN). The randomization was stratified so as to ensure a reasonable treatment balance for prognostic factors that usually render patients ineligible (age > 75 years and baseline ALP > 3 ULN). The Kaplan-Meier method was used to estimate survival and PFS curves, and the log-rank test was used to compare the curves [10] . The Mantel-Haenszel test was used to compare proportions (response rate and toxic effects) [11] .
results
patient characteristics
Sixty-three patients had ALP 3-5 ULN in the OPTIMOX1 study. Their median age was 63 years (range 32-80). Of these, original article Annals of Oncology FOLFOX7/stop-and-go. Patient characteristics were similar between arm A and arm B (Table 1) . Forty-six patients (73%), 23 in each arm, had a performance status of one or two. The primary tumor site was rectal in 18 patients (29%). Forty-four patients (70%) had only one metastatic site, usually in the liver (87%), whereas lung metastases were found in nine patients (14%). Lactate dehydrogenase (LDH) level was increased in 48 patients (76%). Characteristics of patients with ALP 3-5 ULN and £3 ULN are summarized in Table 1 .
treatment and outcomes
In total, patients received 766 cycles of treatment, including 541 cycles with oxaliplatin. The median number of cycles with oxaliplatin was 9.9 (range 1-22) in arm A and 7.1 (1-18) in arm B. In arm A, 25 patients (75%) had more than six cycles of FOLFOX4 in first-line therapy. In arm B, 21 patients (70%) received the six planned cycles of FOLFOX7. Only nine patients in arm B (30%) had a per-protocol oxaliplatin reintroduction. Reasons for no reintroduction were progression in five patients, investigator's decision in four patients, neurotoxicity in four patients, death in four patients and surgery of metastasis in one patient.
The majority of patients went on to receive further lines of therapy after completing the treatment stipulated in the study protocol. In arm A, 22 patients (66%) received a second-line treatment, of whom 20 received an irinotecan-based regimen. One partial response and five stabilizations were observed in these patients. Twelve patients received a third-line therapy and two a fourth treatment line. In arm B, 20 patients (66%) received a second-line treatment, of whom 16 received an irinotecan-based regimen. There were only three patients with stable disease. Of note, the response rate of second-line irinotecan-based chemotherapy was only 2.4%.
In arm A, 25 patients died of CRC, two of thromboembolic event and two of unknown cause. In arm B, 23 patients died of CRC, two of thromboembolic event and three of other or unknown cause.
responses Fifty-three patients were assessable for response. Nine patients received only one cycle of chemotherapy, and tumor evaluation was not performed in one patient. The overall response rate (complete response plus partial response) was 56% [95% confidence interval (CI) 44% to 68%] for all patients, 48% in arm A (95% CI 31% to 65%) and 63% in arm B (95% CI 45% to 81%]. In total, 16% of the patients had stabilization and 13% had progression. The 56% response rate was comparable to the 59% response rate observed in patients with ALP £3 ULN ( Table 2 ). R0 surgery for metastases was carried out in only one patient in both arms. Among the nine patients in arm B who had a per-protocol oxaliplatin reintroduction, one had a partial response following reintroduction, four patients had a stable disease and four had a progression.
PFS and OS
Median DDC and median PFS were both 6.4 months. Median PFS was 6.7 months in arm A (95% CI 5.3-8.3 months) and 6.5 months in arm B (95% CI 5.5-7.6). Median OS was 11.5 months for all patients, 14 months in arm A (95% CI 8.3-14.9) and 10.5 months in arm B (95% CI 9.0-12.4]. These values were significantly lower than for patients with ALP £3 ULN in the parent study (Table 2, Figure 1 ). 
discussion
The results in this study were consistent with previous findings that ALP is one of the key prognostic factors for MCRC [3, 5, 6] . However, the OPTIMOX1 trial demonstrates that FOLFOX treatment achieves high response rates in patients with ALP 3-5 ULN, similar to those observed in patients with ALP £3 ULN. FOLFOX7 did not improve the response rate over FOLFOX4 which can be explained by the 50% increase in oxaliplatin dose intensity. However, PFS and OS were similar in the two arms. PFS and OS were both shorter for patients with ALP >3 ULN than for patients with ALP £3 ULN. Median OS was almost 1 year, which is 5 months longer than LV and 5-FU alone in this particular setting [6] . Furthermore, patients demonstrated good treatment tolerability, at least comparable to patients with ALP £3 ULN. On the basis of these results, we conclude that FOLFOXbased therapy provides a beneficial palliative option for these patients.
The results of this study reinforce the need for careful stratification of patients with advanced CRC. The three prognostic groups on the basis of performance status, white blood cell count, ALP level and the number of metastatic sites identified by Köhne et al. seem to be applicable to patients with MCRC treated with first-line oxaliplatin or irinotecan-based chemotherapy, in whom median survival is longer [6, 12] .
Alongside ALP and the prognostic factors used in the Köhne study, other prognostic markers are available [13] . One such factor is LDH, which was not used in multivariate analysis of Köhne et al. despite a strong association with survival in the univariate analysis because data were missing in approximately two-third of cases [6] . In our previous studies including OPTIMOX1, PS and LDH are the strongest independent prognostic factors [3, 5, 7] .
While these data demonstrate the value of prognostic markers, there is clearly a need for greater standardization and for further data on the optimal approaches to treatment in different prognostic groups. The aim of clinical research should not be limited to the discovery of new antineoplastic agents or drug combinations, but should also help clinicians determine an optimal therapeutic strategy for each of their patients. Future clinical studies should integrate the analysis of prognostic factors into their design and include poor prognosis cohorts.
In conclusion, the results of this study support the use of FOLFOX in poor prognosis patients with MCRC. 
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